<DOC>
	<DOCNO>NCT02089334</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose RX-0201 , target dose 250 mg/m^2/day , give combination everolimus ( Stage 1 ) , assess safety efficacy RX-0201 plus everolimus , subject metastatic renal cell cancer ( Stage 2 ) .</brief_summary>
	<brief_title>Dose-Finding , Safety Efficacy Study RX-0201 Plus Everolimus Metastatic Renal Cell Cancer</brief_title>
	<detailed_description>This multi-center , open-label , randomize , parallel group study RX-0201 combination everolimus , versus everolimus alone treat subject advance renal cell carcinoma conduct 2 stage . Stage 1 open-label , dose-escalation study RX-0201 identify safe tolerable dose RX-0201 target dose 250 mg/m^2/day give combination everolimus . Stage 2 randomize , open-label , 2-arm study RX-0201 combination everolimus versus everolimus alone . Subjects receive RX-0201 , dose identify Stage 1 , combination everolimus everolimus alone , 8 cycle determine safety efficacy combination .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Males female â‰¥ 18 year age screen Histological cytological diagnosis renal cell cancer clearcell component Measurable evaluable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) ver . 1.1 Must receive least one course therapy VEGFRtargeting tyrosine kinase inhibitor ( eg , sorafenib , sunitinib , axitinib , pazopanib tivozanib ) progress within 6 month plan first dose study treatment ECOG performance status 0,1 2 Life expectancy &gt; 3 month Provide write informed consent Brain metastases cranial epidural disease unless adequately treat radiotherapy and/or surgery stable least 3 month plan first dose study drug Radiation therapy bone metastasis within 2 week , external radiation therapy within 4 week plan first dose study drug . Systemic treatment radionuclides within 6 week plan first dose study drug . Subjects clinically relevant ongoing complication prior radiation therapy eligible Prior treatment everolimus , specific selective TORC1/PI3K/AKT inhibitor ( eg , temsirolimus ) Receipt type small molecule kinase inhibitor ( include investigational kinase inhibitor ) within 2 week plan first dose study drug Receipt type anticancer antibody ( include investigational antibody ) within 4 week plan first dose study drug Taking strong inducer inhibitor CYP450s subject receive everolimus Chronic treatment corticosteroid immunosuppressive agent Concomitant anticoagulation therapeutic dos oral anticoagulant platelet inhibitor Subjects know hypersensitivity everolimus rapamycins ( sirolimus , temsirolimus ) excipients Major surgery within 2 month plan first dose study drug Myocardial infarction within previous 6 month plan first dose study drug Active infection require parenteral antibiotic within 2 week plan first dose study drug Diagnosis another malignancy within 2 year plan first dose study drug , except superficial skin cancer , localize , low grade tumor Prior current history hepatitis B , hepatitis C human immunodeficiency virus Sexually active fertile subject ( male female ) must agree use medically accept method contraception course study 30 day last dose study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>renal cell carcinoma</keyword>
	<keyword>clear cell</keyword>
	<keyword>renal cancer</keyword>
	<keyword>metastatic renal cancer</keyword>
	<keyword>Carcinoma , Renal Cell*/therapy</keyword>
	<keyword>Humans</keyword>
	<keyword>Kidney Neoplasms*/therapy</keyword>
</DOC>